OpenEvidence is leveraging a partnership with a top cancer center to bolster its oncology capabilities, adding trusted genomic interpretation expertise to the AI platform already used by millions of clinicians.
Through the partnership, the company will integrate a precision oncology knowledge base directly into its workflows for expanded use by providers. OpenEvidence previewed the partnership exclusively with Fierce Healthcare, referring to the partner as a "nationally leading cancer center," with plans to identify the organization next week.
The partnership brings precision oncology decision support to clinicians nationwide and deepens OpenEvidence's push into cancer care as the company already directly integrates the foundational frameworks of cancer treatment into its medical search engine. The company has a licensing agreement with the National Comprehensive Cancer Network (NCCN) which integrates its evidence-based oncology guidelines into its platform. The company also integrates ASCO Guidelines, figures and flowcharts into its model.
Through its latest partnership with a leading cancer center, OpenEvidence users gain access to expert-curated interpretations of cancer genomic alterations alongside patient-specific context and peer-reviewed evidence, helping clinicians make more informed treatment decisions, according to OpenEvidence executives.
The partnership also builds on OpenEvidence's vision to develop “medical superintelligence” based on agentic artificial intelligence, or a system of AI agents that can be subspecialists in clinical areas, as OpenEvidence founder Daniel Nadler, Ph.D. detailed back in January at the 2026 J.P. Morgan Healthcare Conference.
OpenEvidence has set its sights on building medical specialist AI models, starting with oncology.
Just as neural networks digitally recreated the architecture of intelligence, "medical superintelligence" will digitally recreate groups of experts and specialists, "composing many subspecialty expert models to build a single, more powerful intelligent system acting as a full multispecialty care team that every physician can hold in their hand," Nadler told Fierce Healthcare.
The company is now integrating a leading cancer center's precision oncology knowledge base directly into its specialized oncology sub-agent—an AI agent that has already officially digitized the NCCN treatment algorithms, Nadler noted. Nadler said the company has partnered with several nationally-leading cancer centers and those partnerships would be announced "in the coming weeks."
"In the near future, we will be rolling out the next OpenEvidence specialist agents, in genetics, cardiology and neurology. Our vision is that, in aggregate, this dynamic ensemble of medically specialized agents will not only transcend the limitations of any individual human expert but will also result in a seismic-scale equalization of healthcare quality in America. This will allow every rural or under-resourced county in the country—whose physicians historically had scarce access to sub-specialist knowledge—to carry in their white coat pocket a world-class multispecialty care team or tumor board, on-call 24/7—for free," Nadler said.
OpenEvidence developed an AI-powered medical search engine and a generative AI chatbot exclusively for doctors, which summarizes and simplifies evidence-based medical information. As of September, there were 1.12 million medical licensed-verified U.S. clinicians, including nurses, nurse practitioners and physician assistants, using OpenEvidence.
August is tracking to over 40 million NPI-verified queries from U.S. clinicians in the last 30 days, Nadler told Fierce Healthcare.
The company also released a new family of medical AI models, including OpenEvidence Darwin, what the company calls its most advanced medical AI model, which is now in research preview.
According to OpenEvidence, Darwin is the first AI model in history to achieve a perfect score on MedQA, a fully-independent medical AI benchmark. The company also touted Darwin's performance on other leading benchmarks of medical AI: MedXpertQA (72.8%), HealthBench Professional (82.7%) and NOHARM (87.2%), ahead of the next-best models (Claude Fable 5 and Gemini 3.7).
Darwin is available by application only, currently being used by institutional partners such as the National Organization for Rare Disorders (NORD), research collaborators and accredited AI researchers at academic institutions, the company said. "As Darwin's safeguards are validated with these partners, its capabilities will flow, model by model, into Osler, Sackett, and Snow — the frontier arriving at the point of care as fast as it can arrive safely," the company said.
The company named the models after the founders of modern medicine. OpenEvidence said it built Osler (named for William Osler), what it calls its fastest model that provides answers in about five seconds, for the pace of point of care. Osler is the successor to the model that currently powers OpenEvidence answers, and will continue to be the default model on the platform, the company said.
OpenEvidence Sackett (named for David Sackett) is a deeper search model for questions that turn on the weight of the evidence, according to the company, and Snow (named for John Snow) is OpenEvidence's deepest production model that runs a full investigation of world medical literature before providing a report.
"Every model in the family is held to the same standard of clinical accuracy. What varies is time: how long a model thinks, and how deep it searches," the company said in a blog post.
The company said the Osler, Sackett and Snow models are rolling out to all OpenEvidence users today—free to verified clinicians.